Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2955-2958

  Gaarenstroom, Katja N ^a   Bonfrer, Johannes M G ^b   Korse, Catharina M ^b   Kenter, Gemma G ^a   Kenemans, Peter ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Cyfra 21 1; Extracervical disease; Prognosis; SCC Ag; TPA

Indexed keywords

CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

BLOOD LEVEL; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANTIGENS, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATINS; PROGNOSIS; SERPINS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0030757773     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Montag ThW: Tumor markers in gynecologic oncology. Obstet Gynecol Survey 45: 94105, 1990.
2. Mellerick DM, Osborn M and Weber K: On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 5: 1007-1017, 1990.
3. Moll R: Epithelial tumor markers: cytokeratins and tissue polypeptide antigen (TPA). Curr Topics Pathol 77: 71-101, 1987.
4. Bodenmuller H, Stieber P, Banauch D, Hasholzner U, Dessauer H and Jaworek O: Enzymun-test Cyfra 21-1: a new marker for NSCLC. Clin Chem 38: 966, 1992.
5. Gaarenstroom KN, Bonfrer JMG, Kenter GG, Korse CM, Hart AAM, Trimbos JB and Helmerhorst ThJM: Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 76: 807-813, 1995.
6. Shepherd JH. Revised FIGO staging for gynaecological cancer: Br J Obstet Gynaecol 96: 889-892, 1989.
7. Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F and Splinter TAW: Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 69: 525-528, 1994.
8. Robertson EA and Zweig MH: Use of receiver operating characteristic curves to evaluate the clinical performance of analytical systems. Clin Chem 27: 1569-1574, 1981.
9. Patsner B, Orr JW and Allmen T: Does preoperative serum squamous cell carcinoma antigen level predict occult extracervical disease in patients with stage Ib invasive squamous cell carcinoma of the cervix ? Obstet Gynecol 74: 786-788, 1989.
10. Crombach G, Würz H, Herrmann F, Kreienberg R, Mobus V, Schmidt-Rhode P, Sturm G, Caffier H and Kaesemann H: Bedeutung des SCC-antigens in der diagnostik und verlaufskontrolle des zervixkarzinoms. Dtsch Med Wochenschr 114: 700-705, 1989.
11. Bolli JA, Doering DL, Bosscher JR, Day TG, Rao CV, Owens K, Kelly B and Goldsmith J: Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the cervix. Gynecol Oncol 55: 169-173, 1994.
12. Yagizi R, Munoz AK, Richardson B and Risser R: Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer. Gynecol Oncol 41: 135-138, 1991.
13. Duk JM, De Bruijn HWA, Groenier KH, Hollema H, Ten Hoor KA, Krans M and Aalders JG: Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. Gynecol Oncol 39: 186-194, 1990.
14. Schmidt-Rhode P, Schulz KD, Sturm G, Hafner H, Prinz H and Kunzig HJ: Squamous cell carcinoma antigen for monitoring cervical cancer. Int J Biol Markers 3: 87-94, 1988.
15. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66, 1993.
16. Rastel D, Ramaioli A and Cornillie F, Thirion B on behalf of the Cyfra 21-1 Multicentre Study Group: Cyfra 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer: report of the first European multicentre evaluation. Eur J Cancer 30A: 601-606, 1994.
17. Kainz Ch, Sliutz G, Mustafa G, Bieglmayr Ch, Koelbl H, Reinthaller A and Gitsch G: Cytokeratin subunit 19 measured by Cyfra 21-1 assay in follow-up of cervical cancer. Gynecol Oncol 56: 402-405, 1995.
18. Ferdeghini M, Gadducci A, Annicchiarico C, Prontera C, Malagnino G, Castellani C, Facchini V and Bianchi: Serum Cyfra 21-1 assay in squamous cell carcinoma of the cervix. Anticancer Rest 13: 1841-1844, 1993